• Media Centre
  • Investor relations
  • Client area
  • Client area
  • Stewardship policy
  • Annual reports service

Form of Proxy

HIKMA PHARMACEUTICALS PLC

Notes

No. Proposition For Against Abstain
1

TO RECEIVE AND ACCEPT THE ACCOUNTS OF THE COMPANY FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025, TOGETHER WITH THE REPORTS OF THE DIRECTORS AND AUDITORS THEREON

2

TO DECLARE A FINAL DIVIDEND ON THE ORDINARY SHARES OF THE COMPANY TOTALLING 48 CENTS PER ORDINARY SHARE IN RESPECT OF THE YEAR ENDED 31 DECEMBER 2025

3

TO RE-APPOINT PWC AS AUDITOR OF THE COMPANY TO HOLD OFFICE FROM THE CONCLUSION OF THE 2026 AGM UNTIL THE CONCLUSION OF THE NEXT GENERAL MEETING

4

TO AUTHORISE THE AUDIT COMMITTEE TO DETERMINE THE REMUNERATION OF THE AUDITOR

5

TO ELECT KHALID NABILSI AS A DIRECTOR OF THE COMPANY

6

TO RE-ELECT VICTORIA HULL AS A DIRECTOR OF THE COMPANY

7

TO RE-ELECT SAID DARWAZAH AS A DIRECTOR OF THE COMPANY

8

TO RE-ELECT MAZEN DARWAZAH AS A DIRECTOR OF THE COMPANY

9

TO RE-ELECT DOUGLAS HURT AS A DIRECTOR OF THE COMPANY

10

TO RE-ELECT ALI AL-HUSRY AS A DIRECTOR OF THE COMPANY

11

TO RE-ELECT CYNTHIA FLOWERS AS A DIRECTOR OF THE COMPANY

12

TO RE-ELECT LAURA BALAN AS A DIRECTOR OF THE COMPANY

13

TO RE-ELECT DR DENEEN VOJTA AS A DIRECTOR OF THE COMPANY

14

TO RECEIVE AND APPROVE THE ANNUAL REPORT ON REMUNERATION (EXCLUDING THE DIRECTORS REMUNERATION POLICY) AS SET OUT IN THE 2025 ANNUAL REPORT

15

TO APPROVE THE DIRECTORS REMUNERATION POLICY, AS SET OUT IN THE 2025 ANNUAL REPORT

16

THAT THE BOARD BE AUTHORISED TO ALLOT SHARES AND TO GRANT RIGHTS TO SUBSCRIBE FOR, OR CONVERT ANY SECURITY INTO, SHARES IN THE COMPANY

17

TO AUTHORISE THE DISAPPLICATION OF PRE-EMPTION RIGHTS (GENERAL)

18

TO AUTHORISE THE DISAPPLICATION OF PRE-EMPTION RIGHTS (ACQUISITION OR CAPITAL INVESTMENT) (SEE NOTICE)

19

THAT THE COMPANY BE AUTHORISED TO MAKE ONE OR MORE MARKET PURCHASES OF ITS ORDINARY SHARES (SEE NOTICE)

20

THAT A GENERAL MEETING OF SHAREHOLDERS OF THE COMPANY OTHER THAN AN AGM MAY BE CALLED ON NOT LESS THAN 14 CLEAR DAYS NOTICE

21

THAT APPROVAL IS GRANTED FOR THE BUYBACK WAIVER

22

THAT APPROVAL IS GRANTED FOR THE 2027 AWARDS WAIVER